2024
High burden of viruses and bacterial pathobionts drives heightened nasal innate immunity in children
Watkins T, Green A, Amat J, Cheemarla N, Hänsel K, Lozano R, Dudgeon S, Germain G, Landry M, Schulz W, Foxman E. High burden of viruses and bacterial pathobionts drives heightened nasal innate immunity in children. Journal Of Experimental Medicine 2024, 221: e20230911. PMID: 38949638, PMCID: PMC11215523, DOI: 10.1084/jem.20230911.Peer-Reviewed Original ResearchConceptsBacterial pathobiontsRespiratory virusesBurden of virusesSARS-CoV-2Innate immune activationSARS-CoV-2 viral loadDynamic host-pathogen interactionsInnate immune responseViral coinfectionCytokine profileViral loadNasal virusImmune activationProinflammatory responseIL-1BNasopharyngeal samplesHost-pathogen interactionsImmune responseInterferon responsePathobiontsInnate immunityPaired samplesCXCL10Healthy 1-year-oldVirusPerformance of two modified two-tier algorithms for the serologic diagnosis of Lyme disease
Landry M, Hassan S, Rottmann B, Pesak S, Ordazzo M, Skrzyniarz M, Deponte S, Peaper D. Performance of two modified two-tier algorithms for the serologic diagnosis of Lyme disease. Journal Of Clinical Microbiology 2024, 62: e00139-24. PMID: 38597655, PMCID: PMC11077974, DOI: 10.1128/jcm.00139-24.Peer-Reviewed Original ResearchConceptsPositive percent agreementSerologic diagnosis of Lyme diseaseDiagnosis of Lyme diseaseEnzyme-linked immunoassayBorrelia speciesTwo-tier algorithmLyme diseaseTwo-tier testImmunoblottingLaboratory diagnosis of Lyme diseaseLIAISON chemiluminescent immunoassaysChemiluminescence immunoassayDetection of IgMScreening testConsensus reference standardSerological diagnosisLaboratory diagnosisDiaSorinIgM resultsIgM detection
2023
Progressive shingles in a toddler due to reactivation of Varicella Zoster vaccine virus four days after infection with SARS-CoV-2; a case report
Miller C, Taylor-Salmon E, Emuren L, Landry M, Gershon A, Miller G. Progressive shingles in a toddler due to reactivation of Varicella Zoster vaccine virus four days after infection with SARS-CoV-2; a case report. BMC Infectious Diseases 2023, 23: 854. PMID: 38057696, PMCID: PMC10698951, DOI: 10.1186/s12879-023-08809-5.Peer-Reviewed Original ResearchConceptsVaricella-zoster virusVZV reactivationVaccine-strain varicella-zoster virusSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Latent varicella zoster virusSymptomatic COVID-19 infectionRespiratory syndrome coronavirus 2SARS-CoV2 infectionSyndrome coronavirus 2COVID-19 infectionVaccine-type strainsSARS-CoV-2Vesicular rashPediatric patientsSignificant morbidityClinical syndromeCoronavirus 2Single doseCase reportGeneral populationMechanical traumaDisease processHZ casesPhysiologic stressLymphocytic Choriomeningitis Virus in Person Living with HIV, Connecticut, USA, 2021 - Volume 29, Number 9—September 2023 - Emerging Infectious Diseases journal - CDC
Dyal J, Gandhi S, Cossaboom C, Leach A, Patel K, Golden M, Canterino J, Landry M, Cannon D, Choi M, Krapiunaya I, Klena J, Shoemaker T. Lymphocytic Choriomeningitis Virus in Person Living with HIV, Connecticut, USA, 2021 - Volume 29, Number 9—September 2023 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2023, 29: 1886-1889. PMID: 37610188, PMCID: PMC10461659, DOI: 10.3201/eid2909.230087.Peer-Reviewed Original ResearchLymphocytic Choriomeningitis Virus in Person Living with HIV, Connecticut, USA, 2021
Dyal J, Gandhi S, Cossaboom C, Leach A, Patel K, Golden M, Canterino J, Landry M, Cannon D, Choi M, Krapiunaya I, Klena J, Shoemaker T. Lymphocytic Choriomeningitis Virus in Person Living with HIV, Connecticut, USA, 2021. Emerging Infectious Diseases 2023, 29 DOI: 10.3201/2909.230087.Peer-Reviewed Original ResearchFailure to Detect Influenza A H1N1 Highlights the Need for Multiple Gene Targets in Influenza Molecular Tests
Landry M, Owen M. Failure to Detect Influenza A H1N1 Highlights the Need for Multiple Gene Targets in Influenza Molecular Tests. Journal Of Clinical Microbiology 2023, 61: e00448-23. PMID: 37338345, PMCID: PMC10358165, DOI: 10.1128/jcm.00448-23.Peer-Reviewed Original ResearchEnhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants
Moriyama M, Lucas C, Monteiro V, Initiative Y, Iwasaki A, Chen N, Breban M, Hahn A, Pham K, Koch T, Chaguza C, Tikhonova I, Castaldi C, Mane S, De Kumar B, Ferguson D, Kerantzas N, Peaper D, Landry M, Schulz W, Vogels C, Grubaugh N. Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2221652120. PMID: 37036977, PMCID: PMC10120007, DOI: 10.1073/pnas.2221652120.Peer-Reviewed Original ResearchConceptsMHC-I expressionBreakthrough infectionsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variantsMajor histocompatibility complex class I expressionCell-mediated immunityInfluenza virus infectionSARS-CoV-2 VOCsMHC-I upregulationClass I expressionSARS-CoV-2T cell recognitionVirus infectionMHC II expressionSpike proteinEnhanced inhibitionInfectionCell recognitionCommon mutationsReinfectionE proteinAntibodiesViral genesSubvariantsExpressionNasal host response-based screening for undiagnosed respiratory viruses: a pathogen surveillance and detection study
Cheemarla N, Hanron A, Fauver J, Bishai J, Watkins T, Brito A, Zhao D, Alpert T, Vogels C, Ko A, Schulz W, Landry M, Grubaugh N, van Dijk D, Foxman E. Nasal host response-based screening for undiagnosed respiratory viruses: a pathogen surveillance and detection study. The Lancet Microbe 2023, 4: e38-e46. PMID: 36586415, PMCID: PMC9835789, DOI: 10.1016/s2666-5247(22)00296-8.Peer-Reviewed Original ResearchConceptsRespiratory virus panelPg/mLCXCL10 concentrationsSARS-CoV-2Bacterial pathobiontsRespiratory virusesSARS-CoV-2 negative samplesViral respiratory infectionsSARS-CoV-2 positive samplesClinical virology laboratoryHealth care systemVirus-positive samplesQuantitative RT-PCRInfluenza C virusSymptomatic patientsRespiratory infectionsSeasonal coronavirusesNasopharyngeal swabsVirus panelC virusCommon virusesCXCL10Host responseInterferon responseVirology laboratory
2022
Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 variants Alpha and Iota
Petrone ME, Rothman JE, Breban MI, Ott IM, Russell A, Lasek-Nesselquist E, Badr H, Kelly K, Omerza G, Renzette N, Watkins AE, Kalinich CC, Alpert T, Brito AF, Earnest R, Tikhonova IR, Castaldi C, Kelly JP, Shudt M, Plitnick J, Schneider E, Murphy S, Neal C, Laszlo E, Altajar A, Pearson C, Muyombwe A, Downing R, Razeq J, Niccolai L, Wilson MS, Anderson ML, Wang J, Liu C, Hui P, Mane S, Taylor BP, Hanage WP, Landry ML, Peaper DR, Bilguvar K, Fauver JR, Vogels CBF, Gardner LM, Pitzer VE, St. George K, Adams MD, Grubaugh ND. Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 variants Alpha and Iota. Communications Biology 2022, 5: 439. PMID: 35545661, PMCID: PMC9095641, DOI: 10.1038/s42003-022-03347-3.Peer-Reviewed Original ResearchRapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons
Chaguza C, Coppi A, Earnest R, Ferguson D, Kerantzas N, Warner F, Young HP, Breban MI, Billig K, Koch RT, Pham K, Kalinich CC, Ott IM, Fauver JR, Hahn AM, Tikhonova IR, Castaldi C, De Kumar B, Pettker CM, Warren JL, Weinberger DM, Landry ML, Peaper DR, Schulz W, Vogels CBF, Grubaugh ND. Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons. Med 2022, 3: 325-334.e4. PMID: 35399324, PMCID: PMC8983481, DOI: 10.1016/j.medj.2022.03.010.Peer-Reviewed Original ResearchConceptsSpike gene target failureSARS-CoV-2 Omicron variantPositivity rateOmicron variantOmicron infectionVaccine dosesVaccine-induced immunityNumber of dosesTest positivity rateOdds of infectionSARS-CoV-2Significant reductionDominant Delta variantUnvaccinated personsVaccination statusHigher oddsDelta variantInfectionVaccine manufacturersDisease controlVirus copiesDosesPCR testOddsTarget failureComparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA
Earnest R, Uddin R, Matluk N, Renzette N, Turbett SE, Siddle KJ, Loreth C, Adams G, Tomkins-Tinch CH, Petrone ME, Rothman JE, Breban MI, Koch RT, Billig K, Fauver JR, Vogels CBF, Bilguvar K, De Kumar B, Landry ML, Peaper DR, Kelly K, Omerza G, Grieser H, Meak S, Martha J, Dewey HB, Kales S, Berenzy D, Carpenter-Azevedo K, King E, Huard RC, Novitsky V, Howison M, Darpolor J, Manne A, Kantor R, Smole SC, Brown CM, Fink T, Lang AS, Gallagher GR, Pitzer VE, Sabeti PC, Gabriel S, MacInnis BL, Team N, Altajar A, DeJesus A, Brito A, Watkins A, Muyombwe A, Blumenstiel B, Neal C, Kalinich C, Liu C, Loreth C, Castaldi C, Pearson C, Bernard C, Nolet C, Ferguson D, Buzby E, Laszlo E, Reagan F, Vicente G, Rooke H, Munger H, Johnson H, Tikhonova I, Ott I, Razeq J, Meldrim J, Brown J, Wang J, Vostok J, Beauchamp J, Grimsby J, Hall J, Messer K, Larkin K, Vernest K, Madoff L, Green L, Webber L, Gagne L, Ulcena M, Ray M, Fisher M, Barter M, Lee M, DeFelice M, Cipicchio M, Smith N, Lennon N, Fitzgerald N, Kerantzas N, Hui P, Harrington R, Downing R, Haye R, Lynch R, Anderson S, Hennigan S, English S, Cofsky S, Clancy S, Mane S, Ash S, Baez S, Fleming S, Murphy S, Chaluvadi S, Alpert T, Rivard T, Schulz W, Mandese Z, Tewhey R, Adams M, Park D, Lemieux J, Grubaugh N. Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA. Cell Reports Medicine 2022, 3: 100583. PMID: 35480627, PMCID: PMC8913280, DOI: 10.1016/j.xcrm.2022.100583.Peer-Reviewed Original ResearchConceptsEnhanced transmissibilitySARS-CoV-2 variant DeltaSARS-CoV-2 Delta variantViral RNA copiesPublic health programsAlpha infectionDelta infectionEffective reproductive numberDelta variantHealth programsVariant DeltaRNA copiesInfectionAlphaReproductive numberTransmissibilityEpidemiological dynamics
2021
A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice
Mao T, Israelow B, Lucas C, Vogels CBF, Gomez-Calvo ML, Fedorova O, Breban MI, Menasche BL, Dong H, Linehan M, Alpert T, Anderson F, Earnest R, Fauver J, Kalinich C, Munyenyembe K, Ott I, Petrone M, Rothman J, Watkins A, Wilen C, Landry M, Grubaugh N, Pyle A, Iwasaki A. A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice. Journal Of Experimental Medicine 2021, 219: e20211818. PMID: 34757384, PMCID: PMC8590200, DOI: 10.1084/jem.20211818.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionChronic SARS-CoV-2 infectionVariants of concernLethal SARS-CoV-2 infectionPost-infection therapyLower respiratory tractPost-exposure treatmentType I interferonSARS-CoV-2Effective medical countermeasuresAdaptive immune systemBroad-spectrum antiviralsContext of infectionSingle doseRespiratory tractViral controlImmunodeficient miceSevere diseaseMouse modelI interferonViral infectionImmune systemInnate immunityDisease preventionConsiderable efficacyUniversal SARS-CoV-2 Testing of Emergency Department Admissions Increases Emergency Department Length of Stay
Sangal RB, Peaper DR, Rothenberg C, Landry ML, Sussman LS, Martinello RA, Ulrich A, Venkatesh AK. Universal SARS-CoV-2 Testing of Emergency Department Admissions Increases Emergency Department Length of Stay. Annals Of Emergency Medicine 2021, 79: 182-186. PMID: 34756452, PMCID: PMC8424016, DOI: 10.1016/j.annemergmed.2021.09.005.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 testingUniversal SARS-CoV-2 testingEmergency department lengthAdmission lengthED admissionPositivity rateSARS-CoV-2 testAcademic health systemCOVID-19 prevalenceSecondary outcomesED lengthPrevention needsED boardingPatientsStayPositive casesClinical costsHealth systemAdmissionTesting policiesContainment effortsTestingPrevalenceTesting changesPositivityFour Human Cases of Eastern Equine Encephalitis in Connecticut, USA, during a Larger Regional Outbreak, 2019 - Volume 27, Number 8—August 2021 - Emerging Infectious Diseases journal - CDC
Brown SC, Cormier J, Tuan J, Lier AJ, McGuone D, Armstrong PM, Kaddouh F, Parikh S, Landry ML, Gobeske KT. Four Human Cases of Eastern Equine Encephalitis in Connecticut, USA, during a Larger Regional Outbreak, 2019 - Volume 27, Number 8—August 2021 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2021, 27: 2042-2051. PMID: 34289334, PMCID: PMC8314835, DOI: 10.3201/eid2708.203730.Peer-Reviewed Original ResearchOutbreak of Acute Respiratory Illness Associated With Human Adenovirus Type 4 at the United States Coast Guard Academy, 2019
Chu VT, Simon E, Lu X, Rockwell P, Abedi GR, Gardner C, Kujawski SA, Schneider E, Gentile M, Ramsey LA, Liu R, Jones S, Janik C, Siniscalchi A, Landry ML, Christopher J, Lindstrom S, Steiner S, Thomas D, Gerber SI, Biggs HM. Outbreak of Acute Respiratory Illness Associated With Human Adenovirus Type 4 at the United States Coast Guard Academy, 2019. The Journal Of Infectious Diseases 2021, 225: 55-64. PMID: 34139752, DOI: 10.1093/infdis/jiab322.Peer-Reviewed Original ResearchConceptsMedical recordsRespiratory outbreaksPolymerase chain reaction testingReal-time polymerase chain reaction testingNew-onset coughPositive patient samplesAdenovirus type 4Cadet trainingRoutine vaccinationSore throatAdenovirus vaccineIllness AssociatedHuman adenovirus type 4Respiratory specimensUnderlying conditionDuty restrictionsReaction testingPatient samplesType 4Whole-genome sequencingSubstantial numberEnvironmental specimensHAdVOutbreakUS Coast Guard AcademyDynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics
Cheemarla NR, Watkins TA, Mihaylova VT, Wang B, Zhao D, Wang G, Landry ML, Foxman EF. Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics. Journal Of Experimental Medicine 2021, 218: e20210583. PMID: 34128960, PMCID: PMC8210587, DOI: 10.1084/jem.20210583.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngiotensin-Converting Enzyme 2Case-Control StudiesChemokine CXCL10COVID-19Disease SusceptibilityFemaleGene Expression ProfilingHost-Pathogen InteractionsHumansImmunity, InnateInterferonsMaleMiddle AgedNasopharynxPicornaviridae InfectionsSARS-CoV-2Viral LoadVirus ReplicationConceptsSARS-CoV-2 infectionSARS-CoV-2 exposureSARS-CoV-2Interferon-stimulated genesUpper respiratory tractRespiratory tractEarly SARS-CoV-2 infectionDynamic innate immune responseViral replicationSARS-CoV-2 replicationPatient nasopharyngeal samplesInnate immune responseLow infectious doseViral loadNasopharyngeal samplesImmune responseInfectious doseISG responseAntiviral responseInfection progressionViral transmissionLevel correlatesInfectionISG inductionInitial replicationMultiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2
Vogels CBF, Breban MI, Ott IM, Alpert T, Petrone ME, Watkins AE, Kalinich CC, Earnest R, Rothman JE, de Jesus J, Claro I, Ferreira G, Crispim MAE, Network B, Singh L, Tegally H, Anyaneji UJ, Africa N, Hodcroft EB, Mason CE, Khullar G, Metti J, Dudley JT, MacKay MJ, Nash M, Wang J, Liu C, Hui P, Murphy S, Neal C, Laszlo E, Landry ML, Muyombwe A, Downing R, Razeq J, de Oliveira T, Faria NR, Sabino EC, Neher RA, Fauver JR, Grubaugh ND. Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2. PLOS Biology 2021, 19: e3001236. PMID: 33961632, PMCID: PMC8133773, DOI: 10.1371/journal.pbio.3001236.Peer-Reviewed Original ResearchReal-world assessment of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) nasopharyngeal swab testing in a region with a high burden of coronavirus disease 2019 (COVID-19)
Sangal RB, Peaper DR, Rothenberg C, Fadlallah H, Mobolaji-Lawal M, Landry ML, Sussman LS, Ulrich A, Venkatesh AK. Real-world assessment of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) nasopharyngeal swab testing in a region with a high burden of coronavirus disease 2019 (COVID-19). Infection Control And Hospital Epidemiology 2021, 43: 1051-1053. PMID: 33823949, PMCID: PMC8111191, DOI: 10.1017/ice.2021.153.Peer-Reviewed Original ResearchEarly introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States
Alpert T, Brito AF, Lasek-Nesselquist E, Rothman J, Valesano AL, MacKay MJ, Petrone ME, Breban MI, Watkins AE, Vogels CBF, Kalinich CC, Dellicour S, Russell A, Kelly JP, Shudt M, Plitnick J, Schneider E, Fitzsimmons WJ, Khullar G, Metti J, Dudley JT, Nash M, Beaubier N, Wang J, Liu C, Hui P, Muyombwe A, Downing R, Razeq J, Bart SM, Grills A, Morrison SM, Murphy S, Neal C, Laszlo E, Rennert H, Cushing M, Westblade L, Velu P, Craney A, Cong L, Peaper DR, Landry ML, Cook PW, Fauver JR, Mason CE, Lauring AS, St George K, MacCannell DR, Grubaugh ND. Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States. Cell 2021, 184: 2595-2604.e13. PMID: 33891875, PMCID: PMC8018830, DOI: 10.1016/j.cell.2021.03.061.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 lineage B.1.1.7SARS-CoV-2 variant B.1.1.7Global public health concernPublic health concernPublic health responseCOVID-19 casesLineage B.1.1.7Variant B.1.1.7Health responseHealth concernB.1.1.7Increased transmissibilityEarly introductionGenomic surveillanceUnited StatesDiagnostic dataDominant lineageViral interference cannot be concluded from datasets containing only symptomatic patients – Authors' reply
Wu A, Mihaylova VT, Landry ML, Foxman EF. Viral interference cannot be concluded from datasets containing only symptomatic patients – Authors' reply. The Lancet Microbe 2021, 2: e10. PMID: 35544223, DOI: 10.1016/s2666-5247(20)30218-4.Peer-Reviewed Original Research